• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Pediatric Infect Dis Soc . A randomized controlled trial to compare immunogenicity to cell-based vs. live-attenuated influenza vaccines in childr

tetano

Editor, Senior Moderator
J Pediatric Infect Dis Soc


. 2023 May 26;piad033.
doi: 10.1093/jpids/piad033. Online ahead of print. A randomized controlled trial to compare immunogenicity to cell-based vs. live-attenuated influenza vaccines in children

Katherine V Williams[SUP] 1 [/SUP], Zhu-Nan Li[SUP] 2 [/SUP], Bo Zhai[SUP] 3 [/SUP], John F Alcorn[SUP] 3 4 [/SUP], Mary Patricia Nowalk[SUP] 1 [/SUP], Min Z Levine[SUP] 2 [/SUP], Sara S Kim[SUP] 2 [/SUP], Brendan Flannery[SUP] 2 [/SUP], Krissy Moehling Geffel[SUP] 1 [/SUP], Amanda Jaber Merranko[SUP] 5 [/SUP], Mark Collins[SUP] 1 [/SUP], Michael Susick[SUP] 1 [/SUP], Karen S Clarke[SUP] 1 [/SUP], Richard K Zimmerman[SUP] 1 [/SUP], Judith M Martin[SUP] 4 [/SUP]



Affiliations
Abstract

Background: Few studies have focused on the immune response to more recent influenza vaccine formulations such as cell-cultured inactivated influenza vaccine (ccIIV4) or live attenuated influenza vaccine (LAIV4) in older children and young adults, or differences in immunoglobulin response using newer antibody landscape technology.
Methods: Participants ages 4-21 were randomized to receive ccIIV4 (n =112) or LAIV4 (n=118). A novel high-throughput multiplex influenza antibody detection assay (MIADA) was used to provide detailed IgG, IgA, and IgM antibody isotypes, along with hemagglutination inhibition levels (HAI), measured pre- and 28 days post vaccination.
Results: The HAI and immunoglobulin isotype response to ccIIV4 was greater than LAIV4, with significant increases in IgG but not IgA or IgM. The youngest participants had the highest LAIV4 response. Prior LAIV4 vaccination was associated with a higher response to current season ccIIV4. Cross-reactive A/Delaware/55/2019(H1N1)pdm09 antibodies were present pre-vaccination and increased in response to ccIIV4, but not LAIV4. Immunoglobulin assays strongly correlated with and confirmed the findings of HAI titers to measure immune response.
Conclusions: Age and prior season vaccination may play a role in the immune response in children and young adults to ccIIV4 and LAIV4. While immunoglobulin isotypes provide high level antigen-specific information, HAI titers alone can provide a meaningful representation of day 28 post vaccination response.

Keywords: MIADA; cell-culture-based inactivated influenza vaccine; egg-based live attenuated influenza vaccine; hemagglutination inhibition assay; influenza; influenza vaccine; randomized controlled trial.

 
Back
Top Bottom